Cargando…

PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)

Detalles Bibliográficos
Autores principales:	Luminari, Stefano, Kim, Tae Min, Risal, Ashish, Namuduri, Manjusha, Cai, Jingxian, Fearon-Chalet, Bertha, Zhu, Min, Mukherjee, Sushmita, Brouwer-Visser, Jurriaan, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Vitolo, Umberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428670/ http://dx.doi.org/10.1097/01.HS9.0000975800.84791.f4

Ejemplares similares

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
por: Novelli, Silvana, et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Mutsaers, Pim G. N. J., et al.
Publicado: (2023)

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
por: Weinstock, Matt, et al.
Publicado: (2022)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Taszner, Michał, et al.
Publicado: (2023)

Efficiency at Olympia
Publicado: (1921)

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Walewski, Jan, et al.
Publicado: (2023)

The Olympia reader : selections from the traveller's companion series /
por: Girodias, Maurice
Publicado: (1967)

Some Notes from the Olympia Motor Show
Publicado: (1919)

Zwischen Corona, Sportmedizin und Olympia in Tokio
por: Engelhardt, Martin
Publicado: (2021)

2267 Radiofrequency renal denervation attenuates kidney fibrosis in spontaneously hypertensive rats
por: Gao, Juan, et al.
Publicado: (2018)

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies
por: Zhu, Min, et al.
Publicado: (2022)

Visit of Ambassador Olympia Neocleous, Permanent Representative of Cyprus to the UNOG
por: Fichet, Jacques Herve
Publicado: (2022)

Consistent differences in fitness traits across multiple generations of Olympia oysters
por: Silliman, Katherine E., et al.
Publicado: (2018)

Response of eelgrass (Zostera marina) to an adjacent Olympia oyster restoration project
por: Briley, Sara, et al.
Publicado: (2021)

2267. Epidemiology of Candida auris Candidemia in a Teaching Hospital in North of Oman: One-Year Survival
por: Eatemadi, Arash, et al.
Publicado: (2019)

PB2267: COVID-19 OUTCOMES ON HAEMATOLOGY PATIENTS WHO RECEIVED RITUXIMAB: SINGLE CENTRE STUDY
por: Hariharan, L., et al.
Publicado: (2022)

Genotoype-by-sequencing of three geographically distinct populations of Olympia oysters, Ostrea lurida
por: White, Samuel J., et al.
Publicado: (2017)

2267. The Effect of Opportunistic Infection (OI) Prophylaxis on the Gastrointestinal Microbiome (GIM) and Immune Reconstitution (IR) in Veterans With HIV and AIDS
por: Skalweit, Marion, et al.
Publicado: (2018)

2267. Evaluation of Antibiotic Prescribing Trends from a Dental Clinic After Implementation of a Dental Antimicrobial Stewardship Initiative
por: Njeim, Noor M, et al.
Publicado: (2023)

Population structure, genetic connectivity, and adaptation in the Olympia oyster (Ostrea lurida) along the west coast of North America
por: Silliman, Katherine
Publicado: (2019)

Conservation aquaculture as a tool for imperiled marine species: Evaluation of opportunities and risks for Olympia oysters, Ostrea lurida
por: Ridlon, April D., et al.
Publicado: (2021)

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
por: Yamauchi, Hideko, et al.
Publicado: (2023)

Temperature and salinity, not acidification, predict near-future larval growth and larval habitat suitability of Olympia oysters in the Salish Sea
por: Lawlor, Jake A., et al.
Publicado: (2020)

Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
por: Yamauchi, Hideko, et al.
Publicado: (2023)

PReS-FINAL-2267: Successful treatment of pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) with combination therapy of sildenafil and ambrisentan: a case report
por: Yamaguchi, KI, et al.
Publicado: (2013)

Examining evidence for neighbourhood variation in the duration of untreated psychosis
por: Kirkbride, J.B., et al.
Publicado: (2010)

Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial
por: Minichsdorfer, Christoph, et al.
Publicado: (2020)

PB2281: TRIAL IN PROGRESS: FOLLICULAR LYMPHOMA OUTCOMES IN RELAPSED/REFRACTORY PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA)
por: Damaj, Gandhi Laurent, et al.
Publicado: (2023)

Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
por: Bugatti, Serena, et al.
Publicado: (2016)

PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
por: Clarke, Jeffrey M., et al.
Publicado: (2022)

Neuropsychiatric symptoms in untreated Parkinson’s disease
por: Szatmari, Szabolcs, et al.
Publicado: (2017)

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
por: Song, Yuqin, et al.
Publicado: (2023)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_grv6sj1219q1kacemo429ioatr